Tranexamic Acid for ACL Injury and Joint Health
This study is looking at whether Tranexamic Acid (TXA), an FDA-approved medication, can help reduce inflammation and improve joint health after an Anterior Cruciate Ligament (ACL) injury and reconstruction surgery. Patients who tear their ACL are at high risk for developing arthritis later on. Researchers believe that TXA, by reducing bleeding and inflammation, might help prevent or delay this. You could be eligible if you are between 18 and 30 years old, had a recent ACL injury (within 4 days), and have swelling or bleeding in your knee. The study will measure inflammation levels in your joint fluid and your knee symptoms after 6 months. The current recruitment status is unclear.
- Study design
- This interventional study plans to enroll 50 participants. It will compare Tranexamic Acid to a placebo (inactive treatment).
- What's involved
- Participants would receive Tranexamic Acid or placebo orally for 5 days and intravenously during ACL reconstruction surgery. Your joint fluid will be measured at Day 5, and you will report on your knee symptoms at 6 months after surgery.
- Compensation
- Not stated in the trial record.
- Follow-up
- Your knee symptoms will be assessed at 6 months after ACL reconstruction surgery.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
The Effects of Tranexamic Acid on Joint Inflammation and Cartilage Health in Anterior Cruciate Ligament Injured Patients
At a glance
Conditions
NCT03552705
Where you'd take part
This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
Stanford University
Stanford, Californiastudy coordinator listed
Recruiting
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Study leadership
- Constance Chu, MD · PRINCIPAL_INVESTIGATOR · Stanford University
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Want this trial checked against your situation?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- Synovial fluid IL-1Day 5
To determine whether TXA administered acutely after ACL injury reduces synovial fluid markers of inflammation and cartilage degradation
- Patient-Reported Outcomes (PRO): Knee injury and Osteoarthritis Outcome Score (KOOS)6 months post-ACLR
To determine whether TXA administered acutely after ACL injury and during ACLR surgery improves PRO (KOOS Quality of Life) at 6 months after ACLR. The Knee injury and Osteoarthritis Outcome Score (KOOS) assesses a patient's opinion about their knee and associated problems. Standardized answer options are given (5 Likert boxes) and each question is assigned a score from 0 to 4. A normalized score (100 indicating no symptoms and 0 indicating extreme symptoms) is calculated.